Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

@article{Reck2016PembrolizumabVC,
  title={Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.},
  author={Martin Reck and D Rodr{\'i}guez-Abreu and Andrew George Robinson and Rina Hui and Tibor Csoszi and Andrea F{\"u}l{\"o}p and Maya Gottfried and Nir Peled and Ali Hosseini Tafreshi and Sinead D. Cuffe and Mary C. O'brien and Suman Rao and Katsuyuki Hotta and Melanie Ann Leiby and Gregory M. Lubiniecki and Yue Shentu and Reshma A Rangwala and Julie R. Brahmer},
  journal={The New England journal of medicine},
  year={2016},
  volume={375 19},
  pages={
          1823-1833
        }
}
BACKGROUND Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 1,019 CITATIONS

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab

VIEW 9 EXCERPTS
CITES METHODS, RESULTS & BACKGROUND
HIGHLY INFLUENCED

Review of checkpoint immunotherapy for the management of non-small cell lung cancer

  • ImmunoTargets and therapy
  • 2018
VIEW 21 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy.

  • Critical reviews in oncology/hematology
  • 2018
VIEW 8 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.

  • Journal of the National Cancer Institute
  • 2017
VIEW 11 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma

  • Cancer management and research
  • 2019
VIEW 5 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2014
2019

CITATION STATISTICS

  • 73 Highly Influenced Citations

  • Averaged 293 Citations per year over the last 3 years

  • 18% Increase in citations per year in 2018 over 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016

Assessment of pembrolizumab (MK-3475) dosing strategy based on population pharmacokinetics and exposure-response models

T Freshwater, J Stone, R de Greef
  • Presented at the 6th American Conference on Pharmacometrics,
  • 2015

Similar Papers

Loading similar papers…